Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep894 | Late Breaking | ECE2021

Radioactive iodine therapy with recombinant human TSH (rhTSH) for well-differentiated thyroid cancer had no difference in GO outcome; case report

Faki Sevgul , Deniz Serdar , Burçak Cavnar Helvacı , Çağlar Keskin , Burçak Polat , Nilay Yüksel , Şeyda Türkölmez , Oya Topaloğlu , Ersoy Reyhan , BekirÇakir

BackgroundThe risk of cancer is relatively higher in GravesÂ’ patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in intermediate-high risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing GravesÂ’ orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisiting GO has not been specific...